Q-omics provides the consensus-scored DEFB4A profile across patient tissues and cancer cell-line models. DEFB4A expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in STAD. Among the 18 cancer types available for tumor–normal comparison, DEFB4A is differentially expressed in 4, with the highest sampling consensus in UCEC. Additionally, DEFB4A RNA expression shows 7,441 significant protein co-abundance associations, with the highest sampling consensus in HNSC. Together, these results highlight STAD, UCEC, and HNSC as cancer lineages where DEFB4A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DEFB4A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DEFB4A survival associations across molecular data types. DEFB4A RNA expression shows survival associations in the most cancer types (18). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DEFB4A RNA expression–survival associations across cancer types. High DEFB4A expression shows unfavorable associations in STAD, SKCM, LIHC, SCLC, BLCA and THCA. The STAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .004). Together, the overview and detailed table identify STAD as the clearest survival context for DEFB4A RNA expression.
This table summarizes DEFB4A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in UCEC for RNA.
This table ranks reproducible tumor–normal expression differences for DEFB4A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DEFB4A shows higher tumor expression in UCEC, LUAD, LUSC and COAD. The UCEC box plot shows higher DEFB4A RNA expression in tumor versus normal tissue (log2 FC = +1.270, t-test p = .001).
This table shows molecular features associated with DEFB4A in patient tissues and cancer cell lines. In patient samples, DEFB4A shows the broadest associations at the RNA and protein expression levels, with HNSC recurring as the lineage with the largest associated feature set. In cancer cell lines, DEFB4A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and LUNG_NSCLC_LUAD.
